Finance

Lists
Q2 2026 earnings • released • EPS miss -6.12% • Revenue beat +60.34%
See results
GENB:NASDAQ
Generate Biomedicines Inc
$14.35
+3.31%
(+0.46) 1D
$14.35
0.00% (0.00)
After hours
Closed: Aug 7, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GENB...
Open
$14.72
High
$14.72
Low
$14.02
Mkt. cap
1.84B
Avg. vol.
772.67K
Volume
505.96K
52-wk high
$18.16
52-wk low
$11.00
No. of employees
312
Open
$14.72
High
$14.72
Low
$14.02
Mkt. cap
1.84B
Avg. vol.
772.67K
Volume
505.96K
52-wk high
$18.16
52-wk low
$11.00
No. of employees
312
News stories
From sources across the web
Profile
Generate:Biomedicines is a biotechnology company founded in 2018 and headquartered in Somerville, Massachusetts. It specializes in using machine learning to design and optimize proteins for therapeutic applications, with a focus on immunology, oncology, and infectious diseases. Wikipedia
About Generate Biomedicines Inc
CEO-
Employees312
Founded2018
HeadquartersSomerville, Massachusetts, United States
SectorBiotechnology
Websitegeneratebiomedicines.com
Analyst ratings
Based on 4 analysts giving stock ratings to GENB in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for GENB in the last 3 months.
Highest
Current $14.35
$30.00 (+109.06%)
Average
$25.25 (+75.96%)
Lowest
$22.00 (+53.31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$24.00
+67.2%
08/07/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$25.00
+74.2%
08/07/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$30.00
+109.1%
06/24/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
$22.00
+53.3%
05/14/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$26.00
+81.2%
04/09/2026
Eric Schmidt FCA
Cantor Fitzgerald
Buy
Initiated
-
-
03/24/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.52 / -$0.49
-6.12%miss
Revenue / Est. (USD)
6.31M / 3.94M
+60.34%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Mar 2026
Jun 2026
Revenue
8.82M
-
7.22M
6.31M
Cost of goods sold
46.82M
-
57.81M
-
Cost of revenue
46.82M
-
57.81M
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.15M
-
13.52M
-
Operating expense
10.15M
-
13.52M
-
Total operating expenses
56.97M
-
71.34M
-
Operating income
-48.15M
-
-64.11M
-
Other non operating income
-
-
-363.00K
-
EBT including unusual items
-44.26M
-
-61.69M
-
EBT excluding unusual items
-44.26M
-
-61.69M
-
Income tax expense
56.00K
-
28.00K
-
Effective tax rate
-0.13%
-
-0.05%
-
Other operating expenses
-
-
-
-
Net income
-41.68M
-
-61.45M
-
Net profit margin
-472.73%
-517.56%
-850.58%
-
Earnings per share
-
-
-1.07
-0.52
Interest and investment income
4.28M
-
2.91M
-
Interest expense
-368.00K
-
-182.00K
-
Net interest expenses
3.91M
-
2.73M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-46.84M
-
-63.04M
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps